X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

EBioMedicine

期刊標題檢索 EBIOMEDICINE 最新評論: Foreknowledge is a real thing (2024-04-27)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[EBioMedicine]您好,您是該頁面的第 217369 位訪客。

期刊簡介
期刊名稱EBioMedicine EBioMedicine
LetPub Score
7.6
50 ratings
Rate

Reputation
8.4

Influence
6.9

Speed
7.2

期刊簡稱EBIOMEDICINE
ISSN2352-3964
h-index37
CiteScore
CiteScoreSJRSNIPCiteScore Rank
17.703.1931.728
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: General Medicine
Q119 / 636
Category: Medicine
Subcategory: General Biochemistry, Genetics and Molecular Biology
Q115 / 221

自引率 (2023-2024)1.00%自引率趨勢
掲載範囲
The effective translation of insights gained from biomedical research into improved human health is a global priority. To this end, Elsevier has looked to the leadership of its two leading brands, Cell and The Lancet, to guide the launch of a new comprehensive, online-only open access Elsevier journal, EBioMedicine, focused on forming a community that spans this interface and creates a valuable opportunity for dialogue and collaboration between their respective audiences.
官方網站https://www.ebiomedicine.com/
在線稿件提交https://www.editorialmanager.com/EBIOM
開放訪問Yes
出版商Elsevier BV
主題領域Biochemistry, Genetics and Molecular Biology
出版國/地區Netherlands
發行頻率
創刊年0
每年文章數429每年文章數趨勢
黃金OA百分比77.56%
OA Related Info
APC: Yes( USD5000; )
APC waiver:Check Notes
Other charges: No
Keywords: basic science、clinical science、translational、genetics、drug targeting、biomedicine
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
MEDICINE, RESEARCH & EXPERIMENTALSCIEQ112/189
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2352-3964%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 5 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【EBioMedicine】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    BiomedicinesH-index: 0

    CiteScore: 5.20
    Current Research in Translational MedicineH-index: 54

    CiteScore: 7.00
    Life-BaselH-index: 0

    CiteScore: 4.30
    YALE JOURNAL OF BIOLOGY AND MEDICINEH-index: 0

    CiteScore: 5.00
    Biopreservation and BiobankingH-index: 0

    CiteScore: 3.30
    學科內最受檢索的期刊 頁面查看次數
    Biomedicines86216
    Life-Basel42457
    Current Research in Translational Medicine13177
    Biopreservation and Biobanking10846
    YALE JOURNAL OF BIOLOGY AND MEDICINE10368
  •  

    EBioMedicine EBioMedicine
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/20)
  [EBioMedicine] 的評論撰寫評論
作者: 冰心永军


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-27 17:02:51 評論於
Foreknowledge is a real thing
(0) 讚! | 冰心永军

作者: 杨家翠柏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-09 21:53:31 評論於
Feeling lucky!
(0) 讚! | 杨家翠柏

作者: 东风春风


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-08 23:41:54 評論於
Review speed: 2.0 Experience sharing: This magazine is really not simple. The three reviewers are all very strict, and it's tough
(0) 讚! | 东风春风

作者: 神经组织工程


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2024-04-01 19:40:13 評論於
2023.12.11 submitted
2023.12.12 ur (out for review)
2023.12.28 ur
2023.12.29 ur
2023.12.30 rrc
2024.1.2 ur
2024.1.9 ur
2024.1.28 rrc
2024.2.2 revise (4 reviewers)
2024.3.1 revision submitted
2024.3.3 ur
2024.3.5 rrc
2024.3.7 rrc
2024.3.19 rrc
2024.3.20 revise (3 reviewers ok for publication, 1 reviewer has minor statistical concern)
2024.3.26 revision submitted
2024.3.31 accepted
(0) 讚! | 神经组织工程

作者: 乐安小可爱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-28 16:14:10 評論於
Review speed: 1.0 | Submission acceptance rate: 50.0 Experience sharing: After Christmas, the manuscript may actually only take three weeks to return
(0) 讚! | 乐安小可爱

作者: 东风春风


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-16 16:14:49 評論於
Hello, may I ask if there is any update now? I also changed from "required reviewers completed" to "under review" 2 days later, and these two days were weekends. What does it mean when the status changes like this for the first review?
(0) 讚! | 东风春风

作者: 独孤千灵


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-26 22:05:56 評論於
My just required reviews completed have reverted to under review again after 3 days. Have you heard any news?
(0) 讚! | 独孤千灵

作者: 乌龙铃语


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-19 17:05:01 評論於
I am also like this
(0) 讚! | 乌龙铃语

作者: 仲夏宇寰


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-28 21:04:45 評論於
I wonder why "required reviews completed" changed to "under review" the next day
(0) 讚! | 仲夏宇寰

作者: 仲夏宇寰


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-17 08:41:12 評論於
Heavy research direction: translational medicine sharing experience: After submission, it became under review in 3 days, with two date changes in the middle, but it is still in the under review status. What could be the reason for this?
(0) 讚! | 仲夏宇寰

作者: 平原摄提格


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-14 23:11:18 評論於
I will send an email to the editorial department. Each person's situation is different
(0) 讚! | 平原摄提格

作者: 一条小思嫒


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-02 16:50:42 評論於
Hey guys, I just wanted to ask how long it usually takes for the step "Required Reviews Completed" in this magazine. It's been almost a month and there hasn't been any progress
(0) 讚! | 一条小思嫒

作者: 留云弘雅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-21 21:38:25 評論於
Being able to send for review shows that the quality and originality of the article are quite good
(0) 讚! | 留云弘雅

作者: 留云弘雅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-21 12:27:03 評論於
Mediocre articles are basically not submitted for review, this magazine is quite picky now
(0) 讚! | 留云弘雅

作者: Merry Roy


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-16 13:01:31 評論於
How long has it been in the "with editor" status?
(0) 讚! | Merry Roy

作者: 碧水雪风


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-05 09:50:03 評論於
Review speed: 2.0 | Submission acceptance rate: 50.0 
Research focus: Microecology 
Experience sharing: Submitted on June 28th, reviewed in two months. Status changed once in the middle, then back to "under review". Given one month for major revisions, returned for re-evaluation on October 9th
(0) 讚! | 碧水雪风

作者: 李拜天。


領域: 生物学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-23 10:35:06 評論於
I would like to ask, does the first author have to be the owner of the submission account when submitting a manuscript? Can the authors' order be changed? Why can't I find where to do this?
(0) 讚! | 李拜天。

作者: 昆娜沃尔特


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-24 09:05:54 評論於
Research Focus: Translational Medicine Experience Sharing: Three Days of Rejections
(0) 讚! | 昆娜沃尔特

作者: 天神院梦凝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-15 15:40:20 評論於
The mainstream media in the Netherlands and Belgium have fully covered the scientific progress of our COVID-19 research on their front pages: de Volkskrant in the Netherlands: https://www.volkskrant.nl/wetenschap/een-leven-zonder-postcovid-ietsje-dichterbij-amsterdamse-wetenschappers-zitten-op-een-spoor~ba477769/
and the largest newspaper in Belgium, Het Nieuwsblad: https://www.nieuwsblad.be/cnt/dmf20230811_93098420?&articlehash=MkRUxwabcfJ8bfDLtOaVWo7jwbZ98Fjdhc17YhipVT%2BJG2ewmboDCFv2bPfI7eSyC7SSrJoOP3jjQ48jjZz6iIGMQm6Wcm%2FS6KmLKbJ%2B4C9OXC%2FtTlRdKM4QNFBf6610IXzxOOK07HR7N0cNNkNdQD50FmjJnV1EejaVFpkVZcU%2FciMBWRkN%2BY15227Z1Mt3N%2FI6XvlCn%2FPVZn%2Bm%2FWOSogyIJ1speTRBaR0pxjr9EOV4HVfPfvvlcelh3Xm1qzkTD8bKkPuYMPBCTsLJ2HZ1Dv6z95rRtUJb3%2FvoIEgAtV5PUuFoz1JF3T5UUcAppywmhBZmaPG6sVlzeCqH3nwK0Q%3D%3D
(0) 讚! | 天神院梦凝

作者: 震雷鑫鑫


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-16 15:47:48 評論於
Please translate the following paragraph into English and Japanese, and title them as ":" and ":"
(0) 讚! | 震雷鑫鑫

作者: 天神院梦凝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-12 13:35:49 評論於
Our research on PASC, long COVID-19, after 9-10 months of work and two rounds of revision, has just been accepted. Happy! Next step is clinical translation and application
(0) 讚! | 天神院梦凝

作者: 天神院梦凝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-11 22:40:22 評論於
Review speed: 12.0 | Submission acceptance rate: 5.0 Experience sharing: PASC, long COVID-19, review for 9-10 months, really heart-wrenching, but it feels worth it when receiving the acceptance email, the more difficult the peer review, the more I like it
(0) 讚! | 天神院梦凝

作者: Wilbur Salome


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-26 16:18:01 評論於
Vancouver format, you can simply search and download
(0) 讚! | Wilbur Salome

作者: Horace MacMillan


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-26 15:52:59 評論於
Sending for external audit
(0) 讚! | Horace MacMillan

作者: 西域碧菡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-22 11:07:47 評論於
Is it under review the next day after submission? Is it sent for external review or is the editor reviewing it?
(0) 讚! | 西域碧菡

首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/20)

開始撰寫 [EBioMedicine] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*